Our previously published data have shown that targeting HDAC6 (i.e., depletion/inhibition of HDAC6) could sensitize NSCLC cell lines to cisplatin regardless of their p53 status35 (and data not shown). The gene discussed is TP53; the disease is non-small cell lung carcinoma.